XtalPi Launched Kodexia siRNA Discovery Platform
The new closed-loop system uses generative AI to accelerate therapeutic development and molecular design.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe AI-driven platforms will successfully accelerate the development of new medical treatments?
XtalPi has debuted Kodexia, a closed-loop platform designed to streamline siRNA discovery through generative AI and automated laboratory testing. The system has already advanced six proprietary therapeutic programs targeting a variety of medical conditions.
Why it matters
The platform seeks to overcome industry challenges like fragmented design workflows, patent hurdles, and the difficulty of achieving extrahepatic delivery in siRNA treatments. By integrating modeling with automation, it aims to significantly speed up the path from molecular design to therapeutic candidate selection.
The Kodexia platform supports over 500 in vitro and 30 in vivo experiments weekly. It enabled a lead program for IgA nephropathy to reach non-human primate efficacy data in seven months.
The players
XtalPi
XtalPi is a technology company with headquarters in Boston and Beijing that specializes in using artificial intelligence for drug discovery.
The details
Kodexia integrates sequence design, chemical modifications, and patent strategy to optimize the development of siRNA therapeutics. The system utilizes generative models that operate continuously alongside automated labs to refine potential drug candidates.
Timeline
October 6, 2026: XtalPi officially debuted the Kodexia platform.
The Big Picture
The platform extends the capabilities established by the Alnylam Pharmaceuticals siRNA platform by incorporating generative AI and high-throughput automation. This shift signals an industry-wide transition toward fully integrated, closed-loop systems for complex molecular engineering.
For patients, this technology could eventually lead to faster development timelines for novel treatments addressing metabolic and central nervous system diseases. Developers may see improved efficiency in their workflows as automation reduces the time required for validation experiments.
The takeaway
The successful integration of AI into biological modeling demonstrates that high-throughput automation can reliably shorten drug development cycles. Adopting such platforms may become a standard approach for firms looking to clear the patent and delivery barriers currently limiting siRNA therapies.
What happens next
The lead IgA nephropathy program is scheduled to reach preclinical candidate selection within nine months.
Further reading
Learn more about the evolving landscape of medical innovation in the Biotech section.
Live Poll
Do you believe AI-driven platforms will successfully accelerate the development of new medical treatments?
